menu
    • menu
    [{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"225-Ac AKY-1189","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aktis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"255-AC AKY-1189","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aktis Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aktis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"AKY-1189","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ RA Capital Management"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ Cowen","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ Cowen"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":1.1599999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.1599999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ EcoR1 Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Aktis Oncology

    Menu

    Aktis Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac AKY-1189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of [225Ac]Ac-AKY-1189 in Patients with Solid Tumors

                            Details : 225-Ac AKY-1189 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Transitional Cell.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 13, 2025

                            Lead Product(s) : 225-Ac AKY-1189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 255-AC AKY-1189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aktis Oncology Starts Phase 1B Trial of Nectin-4 Radiopharmaceutical AKY-1189

                            Details : AKY-1189 is a potential first-in-class novel Nectin-4 targeted radiopharmaceutical product candidate that has previously demonstrated substantial tumor uptake across several solid tumor types.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 28, 2025

                            Lead Product(s) : 255-AC AKY-1189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKY-1189

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Lilly-Partnered Radiopharma Startup Aktis Oncology Raises $175M

                            Details : The proceeds will advance the company's differentiated radiopharmaceuticals, including its first-in-class Nectin-4-targeted miniprotein radioconjugate, AKY-1189 in development for several tumor types.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : AKY-1189

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,160.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aktis Oncology Collaborates with Lilly on Anticancer Radiopharmaceuticals

                            Details : Aktis and Lilly collaborate to develop differentiated radiopharmaceutical therapeutics for solid tumors, combining Aktis' platform & Lilly's expertise in oncology drug development & commercialization.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $60.0 million

                            May 21, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,160.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Cowen

                            Deal Size : $161.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

                            Details : The additional funding will fuel the advancement of the miniprotein programs into the clinic and enable further investment in the differentiated development capabilities as well as end-to-end supply chain and distribution strategy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 25, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Cowen

                            Deal Size : $161.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers

                            Details : The agreement provide Aktis with a portfolio of suppliers that utilize varied techniques to produce high quality Actinium-225, and enhance the Company’s ability to ensure delivery of finished targeted radioconjugates to healthcare providers for adminis...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 23, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aktis Oncology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : EcoR1 Capital

                            Deal Size : $72.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid T...

                            Details : Aktis Oncology is developing novel alpha radiotherapies to improve upon the efficacy of conventional solid tumor therapies, while limiting toxicity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 18, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : EcoR1 Capital

                            Deal Size : $72.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth